Patient P-02041
Metabolic response 45 at the day-84 endpoint (observed).
Responding: response probability 52%, metabolic response 52 today; biology is not blocking the drug.
Drift detected on day 12 (HRV −9 ms, resting HR +11 bpm, sleep −0.9 h, nausea / gi symptoms +46, inflammatory load +43); the side effect would have been reported on day 16 — 4 days of warning.
53 of 61 scheduled doses in the last 60 days are biologically confirmed (87%); 8 were logged but show no dose signature. Dose signature: resting HR +3 bpm, HRV −12 ms.
Trajectory is stable relative to similar patients; keep the current content.
- 🍽Keep meals regular; three to four moderate portions spaced through the day
- 🍽Include a cooked vegetable portion with each main meal
- ✓Log the daily check-in; one line is enough
- ✓Keep the current walking rhythm
- 💊Take the dose at the same time relative to your evening meal
- 💊No additional supplements this week
Adherence is not the problem.
sleep quality falling under 35 while GI rises
P-02041 is on day 141 of META-24 (ET, baseline S06): response stable, tolerance favorable, GI improving. Over 14 days response moved +4 and GI -7; discontinuation risk is 8%. The state is between basins, heading towards restoration, after diverging from the model on day 12.
Biology sets the gain: FUT2 non-secretor, Low butyrate capacity, Low microbial diversity; butyrate capacity 23/100, diversity 2.0. Pushing it down: Escherichia coli 25.768% (LPS load) (-42.1), Low butyrate capacity (-33.1), 5 keystone species absent (-24.8). Pulling it up: GI Support Protocol GI-04 (+56.3), Protein (supports) (+27.3). From the daily log: protein -6.6 GI next day, fat +5.7 GI next day, simple carbs +4.9 GI next day, ultra-processed +3.3 GI next day.
Past actions: GI-04 on day 23 → improved (26%).
No action is indicated now; the trajectory is stable relative to similar patients.
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and events- Day 0 META-24 started — Baseline state S06
- Day 12 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 22 GI-04 recommended — GI Support Protocol GI-04
- Day 23 Patient accepted — Started GI-04 in the companion
- Day 31 GI symptom burden −26% vs expected — GI Support Protocol GI-04
- Day 37 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 12.
- GI instability-7
- Inflammatory activity-5
- Treatment adherence-3
- Toxicity+3
What helped?
- GI Support Protocol GI-04Day 22Result: symptom burden −26%
Daily trackers
Asset settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Heading towards restoration · 80 from the failing basin, 27 from restoration.
- GI Support Protocol GI-04intervention · steering +56.3
- Protein (supports)perturbation · steering +27.3
- Daily walks resumedperturbation · steering +3.3
- Proteinsupporter · GI -6.6 next day
- Escherichia coli 25.768% (LPS load)hidden · steering -42.1
- Low butyrate capacityhidden · steering -33.1
- 5 keystone species absenthidden · steering -24.8
- Dietary fat loadperturbation · steering -23.8
- Dietary fat loaddetractor · GI +5.7 next day
- Simple carbohydratesdetractor · GI +4.9 next day
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-6.6supporter · 95%
- Dietary fat load+5.7detractor · 95%
- Simple carbohydrates+4.9detractor · 95%
- Ultra-processed food+3.3detractor · 60%
- Insoluble fibre-2.9no signal · 54%
- Alcohol-0.4no signal · 15%
DeepGene damage signature
The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.
- 3 opportunists above range: Escherichia coli, Streptococcus gallolyticus, Clostridioides difficile
- 5 keystone species absent
- Shannon 2.27 (expected ≥ 3)
- 9 resistance genes
- Host DNA fragmentation atypical
- Tissue recycling index 56
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 23/100
- Autonomic recovery ↓20
- WearableShort sleep window
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
- HRV
- 50 ms
- Sleep
- 6.4 h
- Steps
- 7,368
- Resting HR
- 69 bpm
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02332 | 51% | S04 | DT-01 | improved | 53 |
| P-02193 | 50% | S14 | DT-01 | improved | 49 |
| P-02662 | 48% | S12 | HY-01 | improved | 47 |
| P-02054 | 46% | S19 | HY-01 | improved | 47 |
| P-02161 | 46% | S15 | HY-01 | improved | 51 |
| P-02578 | 46% | S15 | DT-01 | improved | 55 |
| P-02690 | 46% | S17 | HY-01 | improved | 45 |
| P-02042 | 45% | S11 | HY-01 | improved | 53 |
| P-02122 | 45% | S12 | DT-01 | improved | 53 |
| P-02287 | 45% | S05 | DT-01 | improved | 53 |
| P-02633 | 45% | S10 | DT-01 | improved | 50 |
| P-02039 | 44% | S01 | HY-01 | improved | 57 |